The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Jing, Xie, Xuping, Fontes-Garfias, Camila R., Swanson, Kena A., Kanevsky, Isis, Tompkins, Kristin, Cutler, Mark, Cooper, David, Dormitzer, Philip R., Shi, Pei-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994717/
https://www.ncbi.nlm.nih.gov/pubmed/33767200
http://dx.doi.org/10.1038/s41541-021-00313-8
Descripción
Sumario:Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.

Ejemplares similares